An emerging role of dysfunctional axon-oligodendrocyte coupling in neurodegenerative diseases
Alexandra I. Mot, PhD; Constanze Depp, MSc; Klaus-Armin Nave, PhD

Neurodegenerative diseases comprise a spectrum of illnesses characterized by progressive neuronal, synaptic, and axonal loss. Clinically they manifest as dementia with declining overall cognitive abilities (language, problem-solving, and memory) and/or movement impairments. The neurological symptoms manifested in each disease depends largely on the part of the nervous system that is primarily affected. Classical neurodegenerative diseases in which a large proportion of cases are sporadic include Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). A common risk factor for all of these sporadic neurodegenerative diseases is aging. Life expectancy is increasing globally leading to a steady rise in disease prevalence that is putting an enormous financial burden on the healthcare system. Why aging constitutes the greatest risk factor for neurodegenerative diseases remains poorly understood. Intriguingly, myelinated white matter integrity is significantly affected by aging, more so than gray matter. Recent studies have shown that, in addition to insulating axons to allow faster impulse propagation, oligodendrocytes also play an important role in providing axonal trophic support indepen-
Selected abbreviations and acronyms

- **AD**: Alzheimer disease
- **Aβ**: amyloid-β
- **APP**: amyloid precursor protein
- **ALS**: amyotrophic lateral sclerosis
- **CNP**: 2',3'-cyclic nucleotide phosphodiesterase
- **GCI**: α-synuclein-positive glial cytoplasmic inclusions
- **GDNF**: glial-derived neurotrophic factor
- **MCT1**: monocarboxylate transporter 1
- **MSA**: multiple system atrophy
- **MBP**: myelin basic protein
- **SOD1**: superoxide dismutase 1
- **TPPP/p25α**: tubulin polymerization-promoting protein/p25α

In recent years, our understanding of oligodendrocyte function has seen a paradigm shift that will be relevant for human brain disease and possibly for the development of new therapies. It has become clear that myelinating glial cells maintain the long-term integrity and survival of the axons that they ensheath, independent of the presence or absence of myelin itself. Specifically, oligodendroglial energy metabolism switches after myelination to aerobic glycolysis, where glycolysis products (ie, pyruvate or lactate) are transferred by diffusion into the myelinated axon to support mitochondrial respiration. Diffusion of metabolites through the myelin sheath occurs through minute cytosolic (20 to 300 nanometers wide) channels that coalesce into a continuous system of tubes, collectively termed “myelinic channels.” Indeed, it is the nearly complete encapsulation of axons by myelin itself, which deprives the neuronal compartment of rapid access to extracellular metabolites (ie, glucose), and which makes oligodendroglial metabolic support so important. Unmyelinated axons can also be supported by astrocytes. Thus, similar to astrocytes that drive the “lactate shuttle” at cortical synapses, oligodendrocytes serve the additional function of metabolically supporting the axons they ensheath.

The integrity of myelinic channels is maintained in part by the antagonizing roles of two widely studied myelin structural proteins; myelin basic protein (MBP) which acts as an adhesive zipper in the formation of compact myelin, and 2',3'-cyclic nucleotide phosphodiesterase (CNP) which prevents “complete” myelin compaction. CNP knockout mice show axonal degeneration in myelinated fibers in the presence of functional myelin, demonstrating that oligodendrocytes play an important role in axonal support that is independent of myelination. Conversely, MBP knockout mice (known as “shiverer” mice), are able to support axons and show no axonal loss in the absence of myelination. Recently it has been proposed that oligodendroglial support of axons is controlled by activity-dependent glutamate release that increases oligodendroglial glucose uptake and glycolytic support of fast-spiking axons. In this way, glutamate released from axons activates oligodendroglial N-methyl-D-aspartate (NMDA) receptors which in turn increases the expression of oligodendroglial cell surface glucose transporter 1 (GLUT1). Lactate is subsequently released towards the axon via monocarboxylate transporter 1 (MCT1) and taken up from the periaxial space by axonal monocarboxylate transporter 2 (MCT2), as illustrated in Figure 1. Physiological experiments with the myelinated optic nerve from...
mice with FRET-based ATP sensors in the axonal compartment suggest that lactate support is more critical at higher spiking frequency. However, oligodendrocytes also deliver glucose to the myelinated axons, at least in the subcortical white matter.

**Alzheimer disease**

AD is the most common form of dementia, currently affecting more than 47 million people worldwide. Symptoms include memory loss, problems with language, disorientation, and mood swings, all of which progressively decline during the disease course. Morphologically, this correlates with synapse and neuronal loss apparent as widespread brain atrophy. On a molecular level, AD is characterized by extracellular deposits of amyloid-β (Aβ) and intracellular accumulation of hyperphosphorylated tau. A number of hypotheses have been proposed to explain the mechanism by which these pathophysiological protein aggregates lead to neuronal and synaptic loss in AD. The most common of these is the amyloid cascade hypothesis which postulates that the build-up of Aβ in various forms acts as an initial disease trigger. Aβ is generated from the amyloid precursor protein (APP) by sequential cleavage of the β-secretase (BACE1) and the γ-secretase complex (containing presenilin 1 or PSEN1), mainly in the endolysosomal compartment. While most cases are sporadic, the discovery of inherited forms of the disease has fueled the development of AD mouse models by introducing APP and PSEN1 transgenes harboring human/humanized sequences with familial AD mutations.

Although AD is classically considered a gray-matter disease, white-matter alterations are also common. Several neuroimaging studies have found an exacerbated decline of white matter integrity in AD patients. Intriguingly, this was also shown for presymptomatic adults that were at an increased risk of developing AD. These findings indicate that myelin changes are an early feature of AD and thus could play a key role in disease etiology. Of note, early neuropathological observations by Braak and Braak (1996) suggested an inverse temporal relationship between AD pathology and myelination: late and thinly myelinated regions of the cortex that suffer most from age-dependent myelin breakdown are susceptible to AD pathology, while heavily and early myelinated tracts such as the spinal cord remain unaffected until the late phases of the disease. Such findings prompted Bartzokis to hypothesize that age-related myelin breakdown which is observed in the cortex and the accompanying repair processes are crucial factors initiating AD. This myelin hypothesis centers on the unique vulnerability of oligodendrocytes and myelin to become damaged upon aging due to their high cholesterol and iron content, slow protein, and lipid turnover, the elaborated production and maintenance of the myelin sheath and their continuous proliferation/differentiation throughout life. This hypothesis is supported by electron microscopic analyses of aged brains in non-human primates, and by recent “omic” approaches that show oligodendrocyte/myelin gene and protein modules to be significantly altered in AD patients.

Intriguingly, genome-wide association studies also identified bridging integrator 1 (BIN1), a protein which is primarily expressed by oligodendrocytes, as the second greatest genetic risk factor for AD after ApoE4.

However, only a few patient and animal studies have examined the role of oligodendrocytes and myelin breakdown in AD in more detail. These studies describe focal demyelination around Aβ deposits (as illustrated in Figure 1) and a loss of oligodendrocyte lineage cells in AD patients. Intriguingly, this is met by an increased proliferation response of oligodendrocyte precursor cells in an AD mouse model, a process which seems to fail in AD patients.

Inherently, animal studies aimed at describing oligodendrocyte alterations in AD mouse models are limited to observing myelin changes secondary to AD (neuronal) protein aggregation and do not test Bartzokis’ hypothesis that oligodendrocyte dysfunction drives Aβ production. The neurocentric view of AD has established the dogma that neurons are the primary producers of Aβ and accordingly animal models have been developed in which the transgenes are driven by neuronal promotors, for example the Thy1-driven APP/PSEN1 transgene in the widely used 5xFAD mouse model. However, the Aβ producing machinery, including processing enzymes, is expressed in many non-neuronal cell types including oligodendrocytes. Interestingly, the selective inactivation of Aβ production from excitatory neurons does not affect amyloid burden in an AD mouse model with ubiquitous expression of a mutant APP transgene, which raises a question regarding the extent to which glial cells contribute to Aβ production. The established AD animal models also suffer from ar-
tifacts caused by the use of non-endogenous promoters to drive the expression of the APP and PSEN1 transgenes. These include overexpression of transgenes and an atypical region specificity of amyloid burden. Recently, Saito and colleagues generated several APP knock-in mice in which a humanized and mutated APP

Figure 1. Axon-oligodendrocyte coupling in health and neurodegenerative disease. (A) In the healthy central nervous system, oligodendrocytes provide trophic support to axons by the transfer of energy-rich molecules (ie, lactate) from the oligodendroglial compartment to the axonal compartment. Lactate is released into the periaxonal space via MCT1 and is taken up by axons via MCT2, where it is used to fuel mitochondrial respiration. MBP acts as a zipper in the formation of compact myelin. In the neurodegenerative diseases AD (B), ALS (C), and MSA (D), pathological protein aggregates accumulate in the oligodendroglial cytoplasm and in the periaxonal space which could physically disrupt motor-driven transport and the free diffusion of metabolites (ie, lactate) from the oligodendroglial to the axonal compartment. In ALS, decreased expression of MCT1 would directly impair the ability of oligodendrocytes to provide metabolic support to axons. Demyelination is observed in all three diseases and it is associated with decreased expression of MBP in ALS and MSA. Impaired metabolic support together with mitochondrial dysfunction leads to decreased ATP supply and subsequent axonal dysfunction. Abbreviations: AD: Alzheimer disease, ALS: amyotrophic lateral sclerosis, FUS: fused in sarcoma, Glc: glucose, GLUT1: glucose transporter 1, Lac: lactate, MBP: myelin basic protein, MCT1: monocarboxylate transporter 1, MCT2: monocarboxylate transporter 2, MSA: multiple system atrophy, SOD1: superoxide dismutase 1, TDP43: transactive response DNA binding protein 43, TPPP/p25α: tubulin polymerization-promoting protein p25α.
version is driven by the endogenous promotor. Therefore, these animal models should recapitulate human amyloidosis more closely and will allow for exploring the contribution of different cell types to cerebral Aβ load.

In summary, there is strong suggestive evidence for oligodendrocyte and myelin disturbances in AD. Bartzokis’ hypothesis of myelin breakdown initiating AD was published before the role of oligodendroglia in support of axons was known. Could age-dependent pathological changes in oligodendrocytes compromise this trophic support function rather than myelination status per se? In support of this extended hypothesis, it was shown that myelinic channels, which are necessary for trophic support, are themselves vulnerable to aging, as evidenced by the striking downregulation of CNP in aged mice. It is tempting to speculate about the role of dysfunctional metabolic coupling of oligodendrocytes and axons in the manifestation of AD: one plausible mechanism is a decline of trophic support in aged and structurally perturbed myelin leading to axonal energy deprivation manifesting in impairments of axonal transport, reduced lysosomal acidification, and lysosomal degradation of BACE1 which then exacerbates Aβ production. Such a mechanism would be in accordance with different lines of evidence demonstrating enhancement of Aβ production by pharmacological energy deprivation, reduction of axonal transport rates as well as impairments of lysosomal trafficking. Metabolic support decline could affect tau phosphorylation and accumulation by very similar mechanisms. Intriguingly, a recent study from the Stys lab identified Aβ threads in the periaxonal space underneath the myelin sheath in white-matter regions in an AD mouse model. While difficult to see microscopically, it seems likely that such periaxonal Aβ aggregates are a burden on both communication and metabolite shuttling between the axon and the oligodendrocyte/myelin compartment. This could for example represent an early (premorbid) disease state of the white matter, which is too densely packed to develop “mature” Aβ plaques as observed in the gray-matter. However, Aβ plaques do exist in the white matter in both animal models and patients. In the context of our hypothesis of reduced metabolic support driving Aβ production, such findings could even argue for a vicious circle between disruptive Aβ accumulation and functional loss of oligodendrocyte-axon coupling.

**Amyotrophic lateral sclerosis**

ALS, also known as Lou Gehrig’s disease, is the most common form of motor neuron disease. Characterized by the progressive failure of the motor neurons required for normal muscle function, ALS is a very debilitating and ultimately fatal condition. The majority of ALS cases are sporadic, while only 10% of cases are caused by inherited genetic mutations. To date, mutations in over 20 different genes have been identified as causative of familial ALS. Of these, mutations in the genes encoding superoxide dismutase 1 (SOD1), fused in sarcoma (FUS), transactive response DNA binding protein 43 (TDP43), and hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9ORF72), have been the most widely studied. The discovery of these disease-causing mutations has led to the development of several ALS animal models, of which the mutant SOD1 mouse model has been the most widely used. Both sporadic and familial forms of the disease are clinically and pathologically similar, therefore investigation into the pathogenesis of familial ALS is likely to provide insight into both forms of the disease. Most intriguing is the fact that, although mutant forms of these proteins are ubiquitously expressed, one cell type (the motor neuron) is predominantly affected. While the reasons for the heightened susceptibility of motor neurons to familial ALS-causing mutations remain unknown, the high energetic demand of motor neurons is likely to be an important factor.

More recently it has been recognized that ALS is a non-cell autonomous disease in which glial cells, including astrocytes, microglia, and oligodendrocytes, play an important role in disease pathogenesis. Specifically, the role of oligodendrocytes in supporting axonal energy metabolism, raises the possibility that oligodendrocytes may play a hitherto underestimated role in ALS that is characterized by the deterioration of energy-hungry motor neurons. Some motor neurons can be significantly long (>3 feet) and are therefore particularly dependent on the metabolic support of oligodendrocytes. Indeed, there is a wealth of emerging evidence demonstrating oligodendrogial dysfunction in ALS, as reviewed in ref 49. Multiple recent studies have demonstrated the presence of inclusions that contain ALS-linked proteins within oligodendrocytes. For example, several studies observed the presence of TDP-43-containing oligodendroglial cytoplasmic inclusions.
in the motor cortex and spinal cord of ALS patients\textsuperscript{50-52} and TDP-43 mutant mice.\textsuperscript{65} Another study found FUS-containing oligodendroglial cytoplasmic inclusions in the CNS of ALS patients with mutations in the \textit{FUS} gene, and the abundance of these inclusions correlated with disease onset.\textsuperscript{54} SOD1-containing cytoplasmic inclusions were also recently observed in cultured oligodendrocytes derived from sporadic or familial ALS patients with mutations in the \textit{SOD1} or \textit{TDP-43} genes.\textsuperscript{55} Another study detected mutant SOD1 via immunoelectron microscopy in the periaxonal oligodendroglial cytoplasm of SOD1-G93A mutant mice.\textsuperscript{56} Taken together, these studies indicate that the presence of oligodendroglial inclusions containing ALS-linked proteins is a common pathological feature of multiple sporadic and familial forms of ALS. This leads to the intriguing hypothesis that aberrant protein aggregates in ALS could physically disrupt motor driven transport and the free diffusion of metabolites (e.g., lactate) from the oligodendroglial to the axonal compartment by “clogging” myelinic channels.

Progressive gray-matter demyelination and reactive changes in NG2+ oligodendrocyte progenitor cells (OPCs) were observed in the motor cortex and spinal cord of both sporadic and familial ALS patients as well as in SOD1-G93A mutant mice.\textsuperscript{57} Of particular interest is the fact that oligodendrocytes in the spinal cord of SOD1-G93A mutant mice start to degenerate before the first clinical symptoms of motor neuron degeneration are detectable.\textsuperscript{51,57} Presumably, in an attempt to compensate for this loss, OPCs exhibit increased proliferation and differentiation in the spinal cord of SOD1-G93A mutant mice, essentially replacing the lost oligodendrocytes such that there is no overall change in oligodendrocyte numbers.\textsuperscript{58,59} However, the newly formed oligodendrocytes fail to mature, resulting in progressive demyelination. Failure to mature is evidenced by decreased expression of proteins essential to oligodendrocyte function, including MBP and MCT1,\textsuperscript{65} as illustrated in Figure 1. Decreased MCT1 expression is thought to decrease the ability of oligodendrocytes to export lactate/pyruvate and would therefore limit their ability to provide metabolic support to the axons they ensheath. This is consistent with the fact that decreased MCT1 expression is only seen in affected ALS tissues including the spinal cord and motor cortex while unaffected brain regions show normal MCT1 levels. Indeed the fact that the newly generated oligodendrocytes in the SOD1-G93A mutant mouse spinal cord are often associated with degenerating axons,\textsuperscript{57} indicates that the expression of mutant SOD1-G93A could impair the ability of these oligodendrocytes to provide the necessary trophic support to axons.

Lastly, evidence pointing to a key role for oligodendrocytes in precipitating ALS disease onset, comes from a study which found that selective removal of mutant SOD1 from NG2+ OPCs via PDGFRα-creER driven recombination substantially delayed disease onset and prolonged survival in ALS mice.\textsuperscript{57} This was associated with a rescue in MCT1 expression at disease onset, indicating that oligodendroglial metabolic support of axons could play an important role at disease onset. Further evidence to support this comes from a recent study which showed that human-induced pluripotent stem cell--derived (iPSC-derived) oligodendrocytes obtained from both sporadic and familial (expressing either mutant SOD1 or mutant TDP43) ALS patients were significantly impaired in their ability to produce and release lactate into the extracellular environment, and this decreased motor neuron survival in co-culture.\textsuperscript{55} These studies indicate that in a human neurodegenerative disease oligodendroglial dysfunction likely accelerates disease progression by depriving motor neurons of essential metabolic support.

**Multiple system atrophy**

Multiple system atrophy (MSA) is a late-onset, progressive, neurodegenerative disease involving multiple brain regions and systems including motor impairment, behavioral alterations and autonomic dysfunction.\textsuperscript{60} The majority of MSA cases are sporadic, although a loss-of-function mutation in the \textit{COQ2} gene which encodes the coenzyme Q10-synthesizing enzyme 4-hydroxybenzoate polyprenyltransferase has recently been linked to the disease in a Japanese cohort of patients.\textsuperscript{61} Alongside Parkinson disease and dementia with Lewy bodies, MSA is part of a large group of neurological disorders known as \(\alpha\)-synucleinopathies that are characterized by the presence of \(\alpha\)-synuclein protein aggregates.\textsuperscript{62} The postmortem diagnosis of MSA is based on the identification of \(\alpha\)-synuclein-positive (oligodendro)glial cytoplasmic inclusions (GCIs), which are the distinctive pathological hallmark of the disease.\textsuperscript{63} The pathogenesis of MSA remains poorly understood, therefore replicating the disease in mouse
models has been challenging. To date, the most widely used mouse models of MSA involve the expression of human α-synuclein from oligodendroglial promoters (PLP, CNP, or MBP), all of which replicate the α-synuclein-positive GCI s seen in MSA but fail to fully replicate the disease phenotype.

Unlike Parkinson disease where α-synuclein inclusions are mostly seen in neurons, the presence of α-synuclein inclusions mostly in oligodendrocytes in MSA led to the classification of the disease as a primary oligodendrogliopathy. Although neuronal cytoplasmic inclusions (NCIs) containing α-synuclein are less frequently found in MSA, the fact that the distribution and severity of neurodegeneration reflects subregional GCI densities supports the view that oligodendrocytes play a central role in disease pathogenesis. Similar to Lewy bodies in Parkinson disease, α-synuclein in GCIs in MSA is also phosphorylated at residue Ser-129 and ubiquitinated. The gene for α-synuclein is not abundantly expressed in mature oligodendrocytes, but several studies have shown that α-synuclein oligomers can be released by neurons and then taken up by surrounding oligodendrocytes to form GCIs. Indeed, recent evidence suggests that misfolded α-synuclein may transcytose in a “prion-like” fashion to spread the disease throughout the nervous system. These studies also showed that MSA patient-derived brain biopsy homogenates containing α-synuclein, when injected into mice expressing human wild-type α-synuclein, triggered aggregation, and phosphorylation of the wild-type α-synuclein which initiated a neurodegenerative cascade. Another recent study found that oligodendroglial GCI s-derived α-synuclein was much more potent at inducing α-synuclein aggregation in injected mice when compared with neuronal Lewy body-derived α-synuclein. Furthermore, the same study also found that oligodendrocytes but not neurons transformed misfolded α-synuclein into a GCI-like strain, highlighting the fact that oligodendrocytes play a central role in disease pathogenesis.

Demyelination throughout the nervous system is frequently observed in MSA patients and is associated with a reduction in myelin lipids, including sphingomyelin, sulfatide, and galactosylceramide, all of which play an important role in myelin integrity and function. Furthermore, alterations in the subcellular localization of tubulin polymerization-promoting protein/p25α (TPPP/p25α) in MSA oligodendrocytes is significantly correlated with decreased MBP expression in degenerating tracts, as illustrated in Figure 1. TPPP/p25α is normally expressed in the nucleus, cytoplasm, and cellular processes of myelinating oligodendrocytes and functions in the stabilization of microtubules and the differentiation of oligodendrocytes. The relocation of TPPP/p25α from the nucleus and myelin sheath to the oligodendroglial cytoplasm followed by cytoplasmic accumulation of the protein prior to the formation of α-synuclein aggregates, is believed to be one of the earliest steps in the pathogenesis of MSA. Indeed, the interaction between TPPP/p25α, a potent stimulator of α-synuclein aggregation, and α-synuclein promotes its phosphorylation and aggregation into insoluble oligomers which later form GCIs. Although the cause of TPPP/p25α redistribution in MSA is unknown, one recent study found that TPPP/p25α co-localized with mitochondrial proteins in the oligodendroglial cytoplasm of both sporadic MSA patients and one familial MSA patient carrying mutations in the COQ2 gene. This indicates that mitochondrial dysfunction may lead to secondary TPPP/p25α relocation in both sporadic and familial forms of MSA.

The fact that neurons degenerate in MSA, a disease in which α-synuclein aggregates are primarily found in oligodendrocytes and not in neurons, suggests that α-synuclein aggregates in oligodendrocytes perturb the ability of these cells to provide trophic support to neurons. This is supported by a recent study which found decreased expression of glial-derived neurotrophic factor (GDNF) in transgenic mice expressing human α-synuclein under the control of an oligodendrocytic (MBP) promoter, but no change in GDNF levels were observed in transgenic mice expressing human α-synuclein under the control of an oligodendrocytic (PLP, CNP, or MBP) promoters. Consistent with this, the same study also found decreased GDNF expression in frontal cortex white matter and in the cerebellum of MSA patients. Furthermore, intracerebroventricular infusion of GDNF improved behavioral deficits and ameliorated neurodegenerative pathology in MBP-human-α-synuclein transgenic mice. Likewise, another study treated PLP-human-α-synuclein transgenic mice with rasagiline, a monoamine oxidase-B inhibitor that is reported to increase expression of GDNF, and found that the
drug ameliorated motor deficits and significantly reduced neuronal loss in the striatum, substantia nigra pars compacta, cerebellar cortex, pontine nuclei, and inferior olives.\textsuperscript{14} Taken together, these studies indicate that α-synuclein expression in oligodendrocytes may impact the trophic support provided by oligodendrocytes to neurons, thereby contributing to neurodegeneration in MSA.

**Conclusion**

The emerging role of oligodendrocytes as key players that provide trophic support to neuronal axons has paved the way for a better understanding of the contribution of dysfunctional axon-oligodendrocyte coupling in neurodegenerative diseases. Here we have reviewed the growing evidence demonstrating that oligodendrocyte dysfunction plays an important role in several neurodegenerative diseases, including Alzheimer disease, amyotrophic lateral sclerosis, and multiple system atrophy. Given that aging is the single greatest risk factor for all of these diseases, age-related myelin deterioration could be an underlying neuropathological mechanism leading to neuronal dysfunction. Novel therapeutic approaches aimed at mimicking or increasing trophic support, ideally by restoring axon-oligodendrocyte coupling could be beneficial in a wide range of neurodegenerative diseases.

**Disclosure/Acknowledgements:** The authors declare that they have no conflicts of interest. Our research is supported by grants of the DFG (CNMPB and SPP1757), the Adelson Foundation, and an ERC Advanced grant to KAN. CD is supported by a PhD fellowship of the Boehringer Ingelheim Fonds.

**REFERENCES**

1. Gunning-Dixon FM, Brickman AM, Cheng JC, Alexopoulos GS. Aging of cerebral white matter: a review of MRI findings. Int J Geriatr Psychiatry. 2009;24(2):109-117.
2. Morrison BM, Lee Y, Rothstein JD. Oligodendroglia: metabolic supporters of axons. Trends Cell Biol. 2013;23(12):644-651.
3. Saab AS, Tzvetanova ID, Nave KA. The role of myelin and oligodendrocytes in axonal energy metabolism. Curr Opin Neuropathol. 2013;23(6):1065-1072.
4. Nave KA, Werner HB. Myelination of the nervous system: mechanisms and functions. Annu Rev Cell Dev Biol. 2014;30:503-533.
5. Griffiths I, Klugmann M, Anderson T, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science. 1998;280(5369):1610-1613.
6. Kassmann CM, Lappe-Siefke C, Baes M, et al. Axonal loss and neuroinnervation caused by peroxisome-deficient oligodendrocytes. Nat Genet. 2007;39(8):969-976.
7. Lappe-Siefke C, Goebl S, Gravel M, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet. 2003;33(3):366-374.
8. Fuchschiising U, Supplie LM, Mahad D, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485(7399):517-521.
9. Lee Y, Morrison BM, Li Y, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487(7408):443-448.
10. Simons M, Nave KA. Oligodendrocytes: myelination and axonal support. Cold Spring Harb Perspect Biol. 2015;8(1):a020479.
11. Harauz G, Ladizhansky V, Boggs JM. Structural polymorphism and multifunctionality of myelin basic protein. Biochemistry. 2009;48(34):8094-8104.
12. Snidero N, Velte C, Myllykoski M, et al. Antagonistic functions of MBP and CNP establish cytosolic channels in CNS myelin. Cell Rep. 2017;18(2):314-323.
13. Saab AS, Tzvetanova ID, Trevisiol A, et al. Oligodendroglial NMDA receptors regulate glucose import and axonal energy metabolism. Neuron. 2016;91(1):119-132.
14. Trevisiol A, Saab AS, Winkler U, et al. Monitoring ATP dynamics in electrically active white matter tracts. SciRep. 2017;6.
15. Meyer N, Richter N, Fan Z, et al. Oligodendrocytes in the mouse corpus callosum maintain axonal function by delivery of glucose. Cell Rep. 2018;22(9):2383-2394.
16. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192(1):106-113.
17. Dean DC, 3rd, Hurley SA, Kecskemeti SR, et al. Association of amyloid pathology with myelin alteration in preclinical Alzheimer Disease. JAMA Neurol. 2017;74(1):41-49.
18. Gold BT, Johnson NF, Powell DK, Smith CD. White matter integrity and vulnerability to Alzheimer’s disease: preliminary findings and future directions. Biochim Biophys Acta. 2012;1822(3):416-422.
19. Hoy AR, Ly M, Carlson CM, et al. Microstructural white matter alterations in preclinical Alzheimer’s disease detected using free water elimination diffusion tensor imaging. PLoS One. 2017;12(3):e0173982.
20. Ringman JM, O’Neill J, Geschwind D, et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer’s disease mutations. Brain. 2007;130(Pt 7):1767-1776.
21. Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol. 1996;92(2):197-201.
22. Bartozik G. Alzheimer’s disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging. 2011;32(8):1341-1371.
23. Peters A. The effects of normal aging on myelin and nerve fibers: a review. J Neurocytol. 2002;31(8-9):581-593.
24. McKenzie AT, Moyon S, Wang M, et al. Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer’s disease. Mol Neurodegener. 2017;12(1):82.
25. Seyfried NT, Dammer EB, Swanup V, et al. A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer’s Disease. Cell Syst. 2017;4(1):60-72 e64.
26. De Rossi P, Buggia-Prevot V, Clayton BL, et al. Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts. Mol Neurodegener. 2009;57(1):54-65.
27. Brunka G, Baer K, Buffo A, et al. Dynamic changes in myelin aberrations and oligodendrocyte generation in chronic amyloidosis in mice and men. Glia. 2013;61(2):273-286.
28. Desai MK, Sudol KL, Janelins MC, Mastrogiacomo MA, Frazer ME, Bowlers WI. Triple-transgenic Alzheimer’s disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia. 2009;57(1):54-65.
29. Miliews T, Kirkcalde MT, Halliday GM, Shepherd CE, Vickers JC, Dickson TC. Focal demyelination in Alzheimer’s disease and transgenic mouse models. Acta Neuropathol. 2010;119(5):567-577.
30. Roher AE, Weiss N, Kokjohn TA, et al. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer’s disease. Biochemistry. 2002;41(37):11080-11090.
31. Schmeed LC, Raymick J, Paule MG, Dumas M, Sarkar S. Characterization of myelin pathology in the hippocampal complex of a transgenic mouse model of Alzheimer’s disease. Curr Alzheimer Res. 2013;10(1):30-37.
32. Oakley H, Cole SL, Logan S, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129-10140.
33. Zhang Y, Chen K, Sloan SA, et al. An RNA-seq sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929-11947.
34. Veeraraghaval K, Zhang C, Zhang X, Tanzi RE, Sisodia SS. atrophy and tau-negative deposition of amyloid from synthesis of beta-amyloid by cells other than excitatory neurons. J Neurosci. 2014;34(10):3668-3673.
35. Salto T, Matsuba Y, Mihira N, et al. Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci. 2014;17(5):661-664.
36. Hagemeyer N, Goebels S, Papiol S, et al. A myelin gene causative of a catatonia-depression syndrome upon aging. EMBO Mol Med. 2012;4(6):528-539.
37. Velliquette RA, O’Connor T, Vassar R. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer’s disease pathogenesis. J Neurosci. 2005;25(47):10874-10883.
38. Stokoe D, Lillo C, Falzone TL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer’s disease. Science. 2005;307(5713):1282-1288.
39. Gowrishankar S, Wu Y, Ferguson SM. Impaired JIP3-dependent axonal lysosome transport promotes amyloid plaque pathology. J Cell Biol. 2017;216(10):3291-3305.
40. Mohamed NV, Plouffe V, Remillard-Labrosse G, Planel E, Leclerc N. Starvation and inhibition of lysosomal function increased tau secretion by primary cortical neurons. Sci Rep. 2014;4:5715.
41. van der Hart JM, Nolle A, Zwart R, et al. The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress. Cell Death Dis. 2014;5:e1393.
42. Yanagisawa M, Planell E, Ishiguro K, Fujita SC. Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer’s disease. FEBS Lett. 1999;461(3):329-333.
43. Chu TH, Cummins K, Sparring JS, et al. Axonal and myelin pathology in SxFAD Alzheimer’s mouse spinal cord. PLoS One. 2017;12(11):e0188218.
44. Iwamoto N, Nishiyama E, Ohwada J, Arai H. Distribution of amyloid deposits in the cerebral white matter of the Alzheimer’s disease brain: relationship to blood vessels. Acta Neuropathol. 1997;93(4):334-340.
45. Chia R, Chio A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17(1):94-102.
46. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264(5166):1772-1775.
47. Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65(suppl 1):S3-9.
48. Phillips T, Rothstein JD. Gial cells in amyotrophic lateral sclerosis. Exp Neurol. 2016;279 Pt B:111-120.
49. Nonneman A, Robberecht W, Van Den Bosch L. The role of oligodendroglial dysfunction in amyotrophic lateral sclerosis. Neurodegener Dis Manag. 2014;4(3):223-239.
50. D’Antonio F, Deleus-Hernandez M, Rutherford NJ, et al. Clinical and neuropathologic heterogeneity of C9TID/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 2011;122(6):673-690.
51. Phillips T, Bento-Abreu A, Nonneman A, et al. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain. 2013;136( Pt 2):471-482.
52. Tan CF, Eguchi H, Tagawa A, et al. TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation. Acta Neuropathol. 2007;113(5-6):535-542.
53. Ditsworth D, Maldonado M, McAlonis-Downes M, et al. Mutant TDP-43 within motor neurons drives disease onset but not progression in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133(6):907-922.
Kovacs GG, Laszlo L, Kovacs J, et al. Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies. *Neurobiol Dis*. 2004;17(2):155-162.

Song YJ, Lundvig DM, Huang Y, et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. *Am J Pathol*. 2007;171(4):1291-1303.

Hlavanda E, Kovacs J, Olah J, Orosz F, Medzihradzky KF, Ovadi J. Brain-specific p25 protein binds to tubulin and microtubules and induces aberrant microtubule assemblies at substoichiometric concentrations. *Biochemistry*. 2002;41(27):8657-8664.

Lindersson E, Lundvig D, Petersen C, et al. p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. *J Biol Chem*. 2005;280(7):5703-5715.

Ota K, Obayashi M, Ozaki K, et al. Relocation of p25alpha/tubulin polymerization promoting protein from the nucleus to the perinuclear cytoplasm in the oligodendroglia of sporadic and COQ2 mutant multiple system atrophy. *Acta Neuropathol Commun*. 2014;2:136.

Ubhi K, Rockenstein E, Mante M, et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. *J Neurosci*. 2010;30(18):6236-6246.

Weinreb O, Amit T, Bar-Am O, Youdim MB. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. *Ann N Y Acad Sci*. 2007;1122:155-168.

Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. *Exp Neurol*. 2008;210(2):421-427.
Un papel emergente del acoplamiento disfuncional axón-oligodendrocito en las enfermedades neurodegenerativas

La mielina es producida por células gliales altamente especializadas y permite la propagación rápida del impulso axonal. Estudios recientes muestran que los oligodendrocitos en el sistema nervioso central son, junto con la mielinización, necesarios para la integridad y sobrevida de los axones, independientemente de la presencia o ausencia de mielina. El mecanismo que subyace a este soporte está dado por oligodendrocitos glicolíticos que aportan a los axones metabolitos ricos en energía. Estos hallazgos representan un cambio de paradigma para la función fisiológica de la glía asociada a los axones, y abre la intrigante posibilidad que los oligodendrocitos sean importantes contribuyentes a las enfermedades neurodegenerativas en que se pierden los axones mielinizados, como la Enfermedad de Alzheimer, la esclerosis lateral amiotrófica y la atrofia de múltiples sistemas. La comprensión del papel del acoplamiento del oligodendrocito con el axón en las enfermedades neurodegenerativas puede abrir la vía para el desarrollo de aproximaciones terapéuticas basadas en el metabolismo.